January 2019 DAIT Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Fiscal Year 2020 Concepts

Fiscal Year 2020 Small Business Innovation Research (SBIR) Contract Solicitation Topics

Development of Sample Sparing Assays for Monitoring Immune Responses

For the published request for applications, see the March 27, 2019 Guide announcement, Development of Sample Sparing Assays for Monitoring Immune Responses (U24 Clinical Trial Not Allowed).

Human Leukocyte Antigen (HLA) and Killer-Cell Immunoglobulin-Like Receptor (KIR) Region Genomics in Immune-Mediated Diseases

For the published requests for applications, see the May 2, 2019 Guide announcements:

Immunobiology of Xenotransplantation Cooperative Research Program

For the published requests for applications, see the May 30, 2019 Guide announcements:

Radiation/Nuclear Countermeasure Product Development Support Services Contract

For the published request for proposals, see the April 18, 2019 solicitation, Radiation/Nuclear Medical Countermeasure Product Development Support.

RNCP-Wide Dosimetry Guidance and Monitoring of Sources and Irradiation Protocols

For the published request for proposals, see the January 22, 2019 solicitation, RNCP-Wide Dosimetry Guidance & Monitoring of Sources and Irradiation Protocols (Clinical Trials Not Allowed).

Development of Vaccines for the Treatment of Opioid Use Disorder

For the published broad agency announcement, see the March 20, 2019 solicitation, Development of Vaccines for the Treatment of Opioid Use Disorder.

Characterizing and Improving Humanized Immune System Mouse Models

Broad Agency Announcement—proposed FY 2020 initiative

Contact: Liem Nguyen

Objective:

  • More fully characterize and further develop humanized immune system (HIS) mouse models
  • Conduct direct comparisons of HIS mice derived from fetal versus non-fetal human tissue sources

Description: This is a new initiative and supports research that includes but is not limited to:

  • Optimizing and characterizing HIS mouse models engrafted with fetal or non-fetal tissue sources
  • Direct comparisons of HIS mice generated with human fetal tissue versus non-fetal tissue sources
  • Optimizing and/or developing HIS mouse models that:
    • Recapitulate human innate immunity, T cell function, B cell/antibody responses (subset development and function)
    • Compare engraftment, development, and functional immunity to human pathogens and immune-mediated diseases
    • Demonstrate functional human mucosal immune responses
    • Recapitulate human secondary lymphoid tissue development

Adjuvant Development for Vaccines Against Infectious or Immune-Mediated Diseases

For the published request for proposals, see the July 10, 2019 Solicitation of NIH and CDC for Small Business Innovation Research (SBIR) Contract Proposals (PHS 2020-1).

Adjuvant Discovery for Vaccines Against Infectious or Immune-Mediated Diseases

For the published request for proposals, see the July 10, 2019 Solicitation of NIH and CDC for Small Business Innovation Research (SBIR) Contract Proposals (PHS 2020-1).

Production of Adjuvants

For the published request for proposals, see the July 10, 2019 Solicitation of NIH and CDC for Small Business Innovation Research (SBIR) Contract Proposals (PHS 2020-1).

Reagents for Immunologic Analysis of Non-Mammalian or Underrepresented Mammalian Models

For the published request for proposals, see the July 10, 2019 Solicitation of NIH and CDC for Small Business Innovation Research (SBIR) Contract Proposals (PHS 2020-1).

Content last reviewed on